{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Ghallab AM"],"pubmed_abstract":["Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer as the absence of cell surface receptors renders it more difficult to be therapeutically targeted. Chemokine receptor 2 (CXCR2) has been suggested not only to promote therapy resistance and suppress immunotherapy but it also to possess a positive cross-talk with the multifunctional cytokine transforming growth factor beta (TGF-β). Here, we showed that CXCR2 and TGF-β signaling were both upregulated in human TNBC biopsies. CXCR2 inhibition abrogated doxorubicin-mediated TGF-β upregulation in 3D <i>in vitro</i> TNBC coculture with PBMCs and eliminated drug resistance in TNBC mammospheres, suggesting a vital role for CXCR2 in TNBC doxorubicin-resistance <i>via</i> TGF-β signaling regulation. Moreover, CXCR2 in"],"journal":["Frontiers in pharmacology"],"pagination":["862125"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9065340"],"repository":["biostudies-literature"],"pubmed_title":["CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer."],"pmcid":["PMC9065340"],"pubmed_authors":["Ghallab AM","El Tayebi HM","Eissa RA"],"additional_accession":[]},"is_claimable":false,"name":"CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer.","description":"Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer as the absence of cell surface receptors renders it more difficult to be therapeutically targeted. Chemokine receptor 2 (CXCR2) has been suggested not only to promote therapy resistance and suppress immunotherapy but it also to possess a positive cross-talk with the multifunctional cytokine transforming growth factor beta (TGF-β). Here, we showed that CXCR2 and TGF-β signaling were both upregulated in human TNBC biopsies. CXCR2 inhibition abrogated doxorubicin-mediated TGF-β upregulation in 3D <i>in vitro</i> TNBC coculture with PBMCs and eliminated drug resistance in TNBC mammospheres, suggesting a vital role for CXCR2 in TNBC doxorubicin-resistance <i>via</i> TGF-β signaling regulation. Moreover, CXCR2 in","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-05-30T20:53:15.11Z","creation":"2025-04-04T10:02:05.875Z"},"accession":"S-EPMC9065340","cross_references":{"pubmed":["35517812"],"doi":["10.3389/fphar.2022.862125"]}}